SpaceX or Rocket Lab: Which Space Stock Is the Better Buy for the Next Decade?

The article favors Rocket Lab over SpaceX on valuation, citing Rocket Lab's $38 billion market capitalization and 48x trailing sales versus SpaceX's $2 trillion valuation and 91x P/S ratio. SpaceX's Starlink generated $4.3 billion of quarterly revenue, up 66% year over year, and $1.66 billion of operating income, while its stated $1 trillion revenue target by 2030 appears unlikely against $21 billion of trailing-12-month revenue. Rocket Lab's proposed approximately $8 billion acquisition of Iridium and development of the Neutron rocket could expand its satellite-services and launch capabilities; its trailing revenue was $769 million, up 1,400% over five years.

Analysis

The investable distinction is not launch cadence but whether vertically integrated launch can earn telecom-like returns on satellite capacity. The orbital-AI narrative should be valued as a long-dated option, not near-term earnings: power generation, thermal management, radiation hardening, and terrestrial backhaul remain binding constraints. For SPCX, a premium multiple can persist only if high-margin connectivity continues to fund the capital intensity of constellation replenishment and any compute buildout.

RKLB's proposed combination with IRDM would shift its risk profile from a development-stage aerospace supplier toward a leveraged, regulated communications operator. The critical diligence item is financing: an $8B transaction is material relative to RKLB's equity value, and debt funding would raise interest and refinancing sensitivity while stock funding risks substantial dilution. IRDM's government and enterprise cash flows could lower RKLB's cost of capital over 6-18 months, but change-of-control, spectrum, and national-security reviews can delay synergies and widen the event-risk discount.

Consensus is likely underestimating execution correlation: Neutron development, satellite deployment, acquisition integration, and a large financing all compete for the same management bandwidth and capital pool. Over the next 1-3 months, definitive merger terms and financing commitments matter more than aspirational revenue targets; over 6-18 months, launch milestones, pro forma free-cash-flow conversion, and subscriber economics determine whether RKLB deserves a platform valuation. The bearish thesis is falsified by a largely equity-funded, fixed-price deal plus an on-time Neutron milestone and guidance to positive consolidated free cash flow; absent these, valuation compression is the more probable path.

Key Decisions for Investors

• Do not add RKLB exposure ahead of disclosed consideration, financing, and pro forma leverage. Establish a 6-12 month long only if management demonstrates that the transaction can be funded without material dilution or elevated refinancing risk and provides a credible path to consolidated free-cash-flow breakeven; the key upside is a rerating toward a diversified space-services platform, while the risk is a financing-led 20%+ drawdown.
• Use a 3-month relative-value hedge of short RKLB versus long LHX for portfolios needing to retain defense-space exposure. LHX provides more established defense and classified-space cash flows, while RKLB bears development and transaction risk; target 15-20% relative downside if financing is debt-heavy or regulatory review extends, and stop out on an on-schedule Neutron success paired with accretive deal financing.
• Place an event-driven alert on IRDM rather than initiating merger arbitrage now. Consider a long only after the bid price, cash/stock mix, closing conditions, and committed financing are public and the annualized spread exceeds roughly 8%; a narrow spread before those details would not compensate for regulatory and acquirer-financing failure risk.
• Avoid chasing SPCX solely on the orbital-compute narrative over the next quarter. Reassess after evidence of incremental external revenue, power and launch-capex disclosure, and connectivity margin durability; without those metrics, the valuation is vulnerable to even modest growth or margin deceleration.